 Today I have the pleasure of speaking with Steve Saviak from Vallejo Pharma. How are you today? Very good, Tracy. Nice to be back on your show. I got to tell you. I don't know where to begin with your second quarter results and highlights, but how about we start with the fact that your revenues are up 80%. What more does the investment audience, what more do they need after that? Let's start there. Revenue growth has been key. It's been expected. It's driven by, large part, almost exclusively, by the addition of our three new products that we launched last year around this time. Redesca, our blood thinner, and two asthma therapies enter Xeronet Tectura, and they're starting to show that growth and they're obviously driving the sales up 80% over last year, 14% over the last quarter, so very positive. I think the last time we spoke, we mentioned your growth of your team and how that was increasing your expenses, but undoubtedly that would pay off. Would you say you've been successful with that? We've grown dramatically in the last year in terms of people, and I think you need to have commercial teams out there in order to market products. We've grown to over 100 people from about 25, 30 people in May, June of last year, so that's considerable growth. Naturally, that inflected into our operating expenses and created larger losses in the quarters that fall, but what we're seeing is that those expenses now are flat to tapering off, so we're actually controlling them. Sales grow, so you're seeing that loss diminish, and we think that sometime later this year we should be able to break that into a break-even point. Now, I appreciate, Steve, that you're a purist. You've been in this industry a long time, so you want to talk about your products. Where do we start? Well, our biggest selling product right now is Redesca, as we expected it to be, so Redesca has that short-term revenue and earnings lift for us. It's a blood thinner used across Canada in hospitals primarily. It's the number one seller in its category. We have 54% of what's known as the biosimilar market. We won't get into too much details about biologics and biosimilars, but safe to say that in BST, biosimilars have taken over 80% of the market. In Quebec, they've taken over 70% of the market, and we expect that to follow through in Ontario shortly, Maritimes and out west. So a product that is going to be the driver of our sales growth for the next 12 months or so, after which you'll start to see our two asthma therapies take over more of the sales growth. And what I like about these therapies, we announced them prior on your show. They deal with moderate to severe asthmatics, as we know there's a lot of asthma sufferers in Canada, a lot of them that are not being adequately treated. And what we're seeing with these two drugs is that in terms of new prescriptions being given to patients, that we are now number two behind Simbacourt, which just to put scale on this, Simbacourt is an over $200 million drug. But right now, we are actually gaining more prescriptions, new prescriptions, than products like Brio, which is over $100 million drug, Xen-Hale over $60 million drug. So we're actually beating these or further ahead than these drugs are. So what that leads me to suspect is our two asthma therapies are going to become mainstays in asthma therapy in Canada. And that means significant revenues, we're projecting over $100 million. And it's one thing to project the other side of this that you show. So sales are growing, but sales come from prescriptions. And prescriptions are, as I say, number two to Simbacourt only in terms of new to brand prescriptions. That's a real important metric for us. And I think for your viewers also, people are taking these products and feeling better with them. So in addition to that, I see you've had a TSX listing of common shares and warrants. Can you provide an update on that? The TSX, I think everyone aspires to list on the TSX. It's the most senior exchange in Canada. It gives you visibility not only within Canada, but throughout North America and into Europe. So being accepted to the TSX Big Board Club, if you will, is a true milestone for us and is a testament to how people feel about our future. Not only are shares listed, but we have a series of the ventures listed on the TSX, as well as a couple of series of warrants. So it's a very good visibility factor for us. And I think it's again, it shows the maturity of our company as we're able to meet the TSX listing requirements. And of course, you've been so incredibly busy. I barely know how to ask you this, but what should we expect next quarter, Steve? Well, I think you're going to see the continued sales growth. It is going to be choppy because of the advancement of certain provinces or the delay thereof, and specifically Ontario. When will they adopt a more active biosimilar policy? As I mentioned, other promises have. I expect Ontario will in the coming months, but whether it will be in July or whether it will be in October is hard to say right now. So that will lead to some choppiness, but consider quarter over quarter growth, quarter over quarter margin expansion, loss reduction, and some potential news on business development activities. Always hard to talk about these because they may or may not happen, but we're quite advanced in trying to add products that will leverage our sales force, leverage our commercial team, and we expect to have something we expect without guaranteeing, but certainly have strong feelings that we're going to advance in those areas in the coming months. Well, as usual, Steve, thank you so much for an update on Vallejo Pharma. And for more information, please go to this website. Thank you, Steve. Thanks so much, Tracy.